{"title":"[治疗帕金森氏病的多巴胺激动剂利苏脲]。","authors":"U D Madeja","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The development of fluctuations in disability are a main problem of the levodopa long-term treatment in Parkinson's disease. The early combination of low doses of levodopa with a dopamine agonist as lisuride improves the symptoms of Parkinson's disease as much as a monotherapy but prevents the development of fluctuations in disability and dyskinesias at the same time.</p>","PeriodicalId":7002,"journal":{"name":"Acta histochemica. Supplementband","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The dopamine agonist, lisuride, in the therapy of Parkinson disease].\",\"authors\":\"U D Madeja\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The development of fluctuations in disability are a main problem of the levodopa long-term treatment in Parkinson's disease. The early combination of low doses of levodopa with a dopamine agonist as lisuride improves the symptoms of Parkinson's disease as much as a monotherapy but prevents the development of fluctuations in disability and dyskinesias at the same time.</p>\",\"PeriodicalId\":7002,\"journal\":{\"name\":\"Acta histochemica. Supplementband\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta histochemica. Supplementband\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta histochemica. Supplementband","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[The dopamine agonist, lisuride, in the therapy of Parkinson disease].
The development of fluctuations in disability are a main problem of the levodopa long-term treatment in Parkinson's disease. The early combination of low doses of levodopa with a dopamine agonist as lisuride improves the symptoms of Parkinson's disease as much as a monotherapy but prevents the development of fluctuations in disability and dyskinesias at the same time.